Trigonelline and 4-Hydroxyisoleucine Composition for Dopaminergic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dopamine-related disorders, such as Parkinson's disease, often have significant side effects and do not effectively inhibit neuronal degeneration, while anti-psychotic drugs can cause immobility due to dopamine receptor blockade, necessitating a more effective and gentler therapy with minimal side effects.
Innovation Solution
A pharmaceutical composition comprising trigonelline or its derivatives and 4-hydroxyisoleucine, optionally with excipients, is developed to enhance dopaminergic activity, inhibit prolactin secretion, and act as a muscle relaxant, which is extracted from plant sources and formulated into various dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for dopamine-related disorders are used, then dopamine levels are increased, but significant side effects occur and neuronal degeneration is not effectively inhibited
Solution Approach 1:
The patent changes the chemical parameters by using a combination of trigonelline and 4-hydroxyisoleucine in specific ratios (trigonelline: 30-90%, 4-hydroxyisoleucine: 10-70%) to achieve optimal dopaminergic activity while reducing side effects. This parameter optimization resolves the contradiction between treatment effectiveness and harmful side effects
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining two active ingredients (trigonelline and 4-hydroxyisoleucine) with complementary mechanisms of action. Trigonelline provides dopaminergic activity while 4-hydroxyisoleucine serves as a precursor for dopamine synthesis, creating a synergistic effect that improves reliability while minimizing harmful factors
2Object-affected harmful factors
If anti-psychotic drugs are used to block dopamine receptors, then psychotic symptoms are reduced, but immobility occurs due to dopamine receptor blockade
Solution Approach 1:
The patent uses trigonelline and 4-hydroxyisoleucine as intermediary substances that indirectly modulate dopamine activity rather than directly blocking receptors. This intermediary approach allows symptom management without the severe motor side effects caused by direct receptor blockade, resolving the contradiction between reducing psychotic symptoms and maintaining mobility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition demonstrates dopaminergic activity, reducing symptoms of Parkinson's disease, inhibiting prolactin levels, and minimizing side effects from dopamine receptor antagonists, with selective Monoamine Oxidase-B inhibition and no interaction with tyramine, thus providing a safer and more effective treatment for dopamine-related disorders.
Implementation Method 1
selective Monoamine Oxidase-B inhibition
Data Source
AI summary
The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors.